Healthpoint Ltd and general partner DFB Pharmaceuticals marketed the drug Xenaderm to nursing homes. The ointment was modeled after a drug made prior to 1962 that the FDA never reviewed. In the 1970s, the FDA determined the principal ingredient in Xenaderm was "less than effective."
The settlement includes $33 million to settle Medicaid based claims nationally. Maryland's Medicaid program will get $345,428.
Healthpoint LTD and DFB Pharmaceuticals could not be reached for comment.